Healthcare / Medical DevicesNasdaqCM
$2.85
-0.24 (-7.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-1.1M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$47M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-16.0%
↓Gross Margin
43.2%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
+10.3%
FCF CAGR
—
FCF margin
1.2%
FCF / Net income
-0.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $27.5M · net income $-7.7M · FCF $332000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $27.5M | $27.5M | $41.8M | $24.4M | $44.5M | $27.0M | $9.6M | $27.3M | $26.4M | $20.6M | $14.8M | $10.3M |
| Net Income | $-7.7M | $-7.7M | $6.6M | $485000.00 | $24.2M | $4.1M | $-6.8M | $-1.7M | $-2.0M | $-3.7M | $-346448.00 | $-237267.00 |
| EBITDA | $-9.7M | $-9.7M | $8.5M | $79000.00 | $15.3M | $4.7M | $-7.5M | $-1.4M | $-1.3M | $-3.3M | $-25536.00 | $94342.00 |
| EPS | -0.47 | -0.47 | 0.41 | 0.03 | 1.46 | 0.25 | -0.42 | — | — | — | — | — |
| Gross Margin | 43.2% | 43.2% | 58.4% | 57.6% | 66.5% | 62.8% | 54.8% | 64.4% | 64.0% | 67.0% | 66.5% | 64.1% |
| Operating Margin | -37.5% | -37.5% | 19.4% | -1.6% | 33.3% | 15.2% | -86.0% | -7.2% | -7.6% | -18.1% | -2.5% | -2.2% |
| Net Margin | -28.1% | -28.1% | 15.9% | 2.0% | 54.4% | 15.2% | -71.4% | -6.2% | -7.7% | -18.0% | -2.3% | -2.3% |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | — | — | — | — | — | — | — |
| Current Ratio | 9.72 | 9.72 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $332000.00 | $332000.00 | $-1.1M | $-2.4M | $-1.6M | $-414000.00 | $-793000.00 | $-2.5M | — | — | — | — |
| Returns | ||||||||||||
| ROE | -16.0% | -16.0% | 11.9% | 1.0% | 50.4% | 15.8% | -31.8% | -6.1% | -7.6% | -31.8% | -2.3% | -4.0% |
| Valuation | ||||||||||||
| P/E | — | — | 17.68 | 87.67 | 5.71 | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | 11.40 | 258.42 | 7.44 | — | — | — | — | — | — | — |
| P/B | 0.97 | 0.97 | 2.12 | 0.88 | 2.88 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | -34.3% | -34.3% | 71.3% | -45.2% | — | 182.4% | -64.9% | 3.2% | 28.4% | 39.0% | 44.2% | — |
| EPS Growth | -214.6% | -214.6% | 1266.7% | -97.9% | — | 159.5% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-40.1%
Start / end P/E
n/dx → n/dx
EPS bridge
0.41 → -0.47
Residual
-40.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.